Fig. 4: IDO1 increased the SLC7A11 mRNA stability by increasing m6A deposition.
A SLC7A11 mRNA half-lives (t1/2) were determined by RNA decay rates detected by RT-qPCR in U87 cells. Data were collected at indicated timepoints with Actinomycin D (Act. D) treatment (n = 3 biologically replicates). B The m6A levels of total RNA in U87 and LN229 cells were determined by m6A dot blot. C MeRIP-qPCR analysis was used to determine m6A levels at indicated sites within SLC7A11 mRNA sequence in U87 cells with IDO1 overexpression (n = 3 biologically replicates). D RT-qPCR was used to detect the transcriptional levels of SLC7A11 and GPX4 in IDO1 overexpressed U87 cells with or without STM2457 (STM) treatment for 72 h (n = 3 biologically replicates). Western blotting was used to detect the expression of IDO1, SLC7A11 and METTL3 in U87 cells with IDO1 overexpression with STM2457 treatment for 72 h E or METTL3 knockdown F (n = 3 biologically replicates). G CCK-8 assay was used to detect the cell viability treated with Erastin (20 μM) combined with or without STM2457 (5 μM) for 72 h in U87 cells with IDO1 overexpression. H Colony formation assay was used to detect the colony seeding ability of cells treated with Erastin (5 μM) combined with or without STM2457 (5 μM) for 12 days in U87 cells with IDO1 overexpression. The data are represented as the mean ± standard deviation (SD); *p < 0.05, **p < 0.01, ***p < 0.001, ns not significant.
